Mycophenolate mofetil in liver transplantation

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Orthotopic liver transplantation (OLT) requires effective immunosuppression to prevent rejection.
• Mycophenolate mofetil (MMF) is an immunosuppressive agent evaluated in OLT recipients.
• Combination therapy with other immunosuppressants is common in OLT.

Purpose of the Study:

• To evaluate the pharmacokinetics of MMF in OLT patients.
• To assess the efficacy of MMF as rescue therapy for acute rejection post-OLT.
• To investigate MMF as primary prophylaxis for rejection after OLT.

Main Methods:

• Pharmacokinetic studies were conducted in 11 OLT patients receiving MMF, cyclosporine (CsA), and steroids.
• Rescue therapy involved converting 23 patients with resistant rejection to MMF.
• Dose escalation studies assessed MMF (3.5-5.0 g/d) with reduced CsA and prednisone for primary prophylaxis.
• Dual therapy with MMF and steroids was studied in 4 patients with intolerance to CsA or FK-506.

Main Results:

• MMF pharmacokinetics (Cmax, Tmax, clearance) were characterized and showed no significant changes over 6 months.
• Twenty-one of 23 patients receiving MMF for rescue therapy responded, with 14 achieving resolution of rejection.
• In primary prophylaxis, 7 of 17 patients had no rejection after 3 months; gastrointestinal side effects were common.
• Dual MMF and steroid therapy resulted in resolved rejection in 3 of 4 patients.

Conclusions:

• MMF demonstrates potential as an effective immunosuppressive agent for both primary prophylaxis and treatment of rejection in OLT.
• Adverse events like GI issues and leukopenia were noted.
• Further research is necessary to fully define the role of MMF in OLT immunosuppression.